Imfinzi 120mg Injection

Imfinzi 120mg injection is an anticancer medication in the class of anti-PD-1 monoclonal antibodies, containing the active ingredient durvalumab. It is indicated for the treatment of non-small cell lung cancer (localised to the chest), small cell lung cancer (spread within the lungs), and biliary tract cancers (malignancies of the bile ducts). Inform your doctor if you have undergone an organ transplant, have liver disease, lung or breathing problems, or autoimmune disease (a condition where the body's immune system attacks its own cells) before receiving this injection. Common side effects include cough, upper respiratory tract infections, fatigue, shortness of breath, lung inflammation, and rash. This medication may increase the risk of immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis, which have been documented. Imfinzi injection is not recommended for adolescents and children under 18 years of age. During Imfinzi 120mg treatment, your doctor may periodically monitor white blood cell counts, platelets, blood glucose, electrolytes, and renal function parameters to prevent serious complications. This drug is frequently used in combination with carboplatin or cisplatin for small-cell lung cancer treatment and in combination with gemcitabine for biliary tract cancer treatment. This medication has the potential to cause kidney problems. Inform your doctor if you have been diagnosed with kidney disorders, heart failure, elevated blood cholesterol, or hypertension prior to starting this treatment.

Imfinzi injection uses include: Non-Small Cell Lung Cancer Small Cell Lung Cancer Biliary Tract Cancer

Imfinzi (Durvalumab) 120mg Injection is a PD-L1 immune checkpoint inhibitor used in the treatment of certain cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancer (BTC). It works by blocking the PD-L1 protein, which helps cancer cells evade immune system detection, thereby restoring the body's natural ability to recognize and attack tumours. By enhancing T-cell activity, Imfinzi slows disease progression, reduces tumour size, and improves overall survival rates. As an immunotherapy, it offers a targeted approach with durable responses, making it an important treatment option in advanced cancer care.

Imfinzi 120 is a prescription drug available in injection form. This injection will be given intravenously into a vein in your arm or hand by a healthcare professional in a hospital setting. Do not self-administer this medicine. The dose of the injection will be decided by your doctor based on your disease condition and other factors. During the infusion, you will be monitored for any side effects or reactions to the medication. The infusion usually takes a few hours to complete, and you may need to receive multiple infusions over the course of several weeks.

Imfinzi side effects include: Serious Infection (chills, increased temperature) serious lung infections (pneumonia) fungal infection in the mouth tooth and mouth soft tissue infections flu-like illness overactive thyroid gland that can cause fast heart rate or weight loss inflammation of the lungs (pneumonitis) hoarse voice (dysphonia) abnormal liver tests (aspartate aminotransferase increased; alanine aminotransferase increased) night sweats muscle pain (myalgia) abnormal kidney function tests (blood creatinine increased) painful urination swelling of the legs (oedema peripheral) reaction to the infusion of the medicine that can cause fever or flushing Common Cough upper respiratory tract infections feeling tired shortness of breath inflammation in the lungs rash

Imfinzi 120mg injection has the tendency to cause harm to unborn fetus. Inform your healthcare provider before starting this treatment if you are pregnant, or have a partner who can become pregnant. Your healthcare provider will conduct a pregnancy test before you start treatment with this drug. Discuss effective birth control methods with your healthcare provider and use them during treatment and for 8 weeks after your last dose. It is not known if this drug passes into breast milk. Hence, it is not recommended to breastfeed during this treatment. This drug can increase your risk of sunburn and skin damage, so it is important to wear protective clothing and sunscreen while moving outdoors. If you experience any gastrointestinal symptoms, such as diarrhea, abdominal pain, or nausea, be sure to inform your doctor immediately so that he may prescribe you antiemetic medicines also to prevent the symptoms.